Metabolic and Pharmacokinetic Effects of Oral Cannabidiol in Connemara Ponies

A dataset from a study evaluating the effects of oral cannabidiol (CBD) on metabolic parameters and its pharmacokinetics in Connemara ponies. The study involved 13 ponies, seven with equine metabolic syndrome, treated with CBD or a control for 21 days. It was authored by Kata Wermer and last updated in May 2026.

Use Cases

• Analyzing the relationship between CBD treatment and insulin response based on oral sugar test results
• Modeling CBD and metabolite pharmacokinetics based on reported Cmax, Tmax, and accumulation ratio
• Comparing metabolic parameters like body condition score and triglyceride levels between treated and control groups
• Investigating safety and tolerability of a 21-day oral CBD regimen in ponies

Strengths

• Includes data from a controlled study with 13 subjects stratified by disease status and age
• Reports specific pharmacokinetic metrics, including a mean Cmax increase from 22.79 to 39.93 ng/mL and an accumulation ratio of 2.75
• Provides detailed results for metabolic parameters like insulin change (mean 10.74 μIU/mL) with statistical significance (p=0.046)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small (28.9 KB), indicating limited scope

Provenance

Source

figshare

Collection Method

Experimental study with ponies randomly assigned to CBD-treated or control groups.

Freshness

Last updated 2026-05-14 04:25:26; freshness should be verified